Dosing regimens for treating and/or preventing cerebral amyloidoses

1. A method for treating Alzheimer's disease or cerebral amyloid angiopathy in a patient diagnosed with the same, the method comprising:

administering daily to the patient an effective amount of 2-acetamido-1,2-dideoxynojirimycin (AdDNJ) for a first enzyme enhancement period of about 1 day to about 8 days;

not administering the AdDNJ for a substrate turnover period of about 48 hours to about 96 hours; and then

administering to the patient an effective amount of AdDNJ for a second enzyme enhancement period of about 1 day to about 8 days.

2. The method of claim 1 , wherein the first enzyme enhancement period and the second enzyme enhancement period have the same duration.

3. The method of claim 2 , wherein one or more of the first enzyme enhancement period and the second enzyme enhancement period is a period of about 4 days to about 6 days.

4. The method of claim 1 , wherein the AdDNJ is administered orally.

5. The method of claim 1 , wherein the AdDNJ is administered at a dose in the range of about 3 mg/kg/day to about 300 mg/kg/day.

6. The method of claim 5 , wherein the AdDNJ is administered at a dose of about 100 mg/kg/day.

7. The method of claim 6 , wherein not administering the AdDNJ for the substrate turnover period comprises not administering AdDNJ for a period of about 72 hours.

8. A method for treating Alzheimer's disease or cerebral amyloid angiopathy in a patient diagnosed with the same, the method comprising:

administering daily to the patient an effective amount of 2-acetamido-1,2-dideoxynojirimycin (AdDNJ) for a first enzyme enhancement period of about 5 days;

not administering the AdDNJ for a substrate turnover period of about 72 hours; and then

administering to the patient an effective amount of AdDNJ for a second enzyme enhancement period of about 1 day to about 8 days.

9. A method for treating Alzheimer's disease or cerebral amyloid angiopathy in a patient diagnosed with the same wherein the method comprises:

administering to the patient an effective amount of AdDNJ on a first day;

not administering the AdDNJ on a second day;

administering to the patient an effective amount of AdDNJ on a third day;

not administering the AdDNJ on a fourth day;

administering to the patient an effective amount of AdDNJ on a fifth day; and then

not administering the AdDNJ for a period of about 72 hours.

10. The method of claim 1 , wherein not administering the AdDNJ for a substrate turnover period comprises not administering AdDNJ for a period of about 24 hours.

11. The method of claim 1 , wherein not administering the AdDNJ for a substrate turnover period comprises not administering AdDNJ for a period of about 48 hours.

12. The method of claim 1 , wherein the first enzyme enhancement period is about 3 days and not administering the AdDNJ for the substrate turnover period comprises not administering AdDNJ for a period of about 120 hours.

13. The method of claim 1 , wherein the method comprises alternating between enzyme enhancement periods and substrate turnover periods for a total treatment time of at least 1 month.

14. The method of claim 13 , wherein the total treatment time is at least 3 months.

15. The method of claim 13 , wherein at least one substrate turnover period has a different duration than at least one other substrate turnover period.

16. A kit comprising:

one or more active dosage forms comprising an effective amount of 2-acetamido-1,2-dideoxynojirimycin (AdDNJ);

one or more inactive dosage forms that do not comprise an effective amount of AdDNJ; and

instructions for:

administering the dosage forms for a first enzyme enhancement period of about 1 day to about 8 days;

not administering the dosage forms for a substrate turnover period of about 48 hours to about 96 hours; and then

administering the dosage forms for a second enzyme enhancement period of about 1 day to about 8 days.